CVS|Analyst Targets
CVS|Company Info
CVS|Insider Trading
CVS|Fundamentals
CVS|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.65 | - | - |
| Q2'26 | $1.87 | $2.58 | +38.0% |
| Q1'26 | $2.21 | $2.57 | +16.5% |
| Q4'25 | $1.00 | $1.09 | +8.8% |
| Q3'25 | $1.36 | $1.60 | +17.9% |
| Q2'25 | $1.46 | $1.81 | +23.9% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $105.5B | - | - |
| Q2'26 | $101.1B | $106.1B | +4.9% |
| Q1'26 | $95.0B | $100.4B | +5.7% |
| Q4'25 | $104.6B | $105.7B | +1.0% |
| Q3'25 | - | $102.9B | - |
| Q2'25 | - | $98.9B | - |
CVS|Monthly Returns
Market Data
CVS Stock Snapshot
- Market cap
- 112.33B
- P/E ratio
- 23.0
- Day range
- $87.50 – $90.78
- News sentiment
- 31/100 · Bearish
- Analyst target
- $115.48 (+27.8%)
- Consensus
- Buy · 35 analysts
The technical read on CVS is balanced, which usually means the market is waiting on a catalyst. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.
Reverse DCF
What growth is priced into CVS?
At today's price, CVS Health Corporation needs to grow free cash flow about -1.8% a year for the next 10 years to justify its valuation at a 6.52% cost of capital. Over its actual history it has compounded free cash flow at 11.7% a year, so the market is asking for 13.5 percentage points below its own delivered rate. On that basis CVS looks priced below what its own growth record supports.
- Implied FCF growth
- -1.8%
- Historical FCF CAGR
- 11.7%
- Growth gap
- -13.5 pts
- Verdict
- CHEAP
- Discount rate (WACC)
- 6.52%
- Beta
- 0.51
Behaviour On Record
What CVS's own history says about today's numbers
- Realized volatility (21d)
- 27.9% 73rd pct
- Below its peak
- -22.8%
- vs 200-day average
- -0.4%
- Up days (1y)
- 49%
CVS Health Corporation is currently running 27.9% annualised volatility over the last 21 sessions. Measured against CVS's own 13 years of daily returns rather than a market-wide average, that is the 73rd percentile — a little above its own norm, against a typical reading of 22.8%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
CVS is trading -22.8% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -23.8%, and the deepest was -46.7% in 2024. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.
Price sits -0.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 49th percentile — close to the gap it normally carries. Over the past year CVS closed higher on 49% of sessions, and it is currently 1 session into a falling streak.
On October specifically: over 13 years of records, CVS finished the month higher 6 of 13 times, with a median return of -0.7% and an average of -0.9%. Its strongest month historically has been November at +4.6% on average, its weakest March at -1.3%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: CVS has opened more than 2% away from the prior close in 41 of 3,265 sessions (1.3% of the time), with the largest gaps running +5.1% and -7.4%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, CVS moved an average of 1.6% in the session after earnings, closing higher 2 of those 3 times, with a median move of +0.3% and a largest of -3.0%.
All figures computed from 3,266 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against CVS's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of CVS's sector?
CVS Health Corporation sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).
- Sector rank
- #2 of 12
- Sector state
- Leading
- Sector rotation score
- 82
Analyst Rating Changes
Are analysts turning bullish or bearish on CVS?
Leerink Partners most recently reiterated its rating on CVS Health Corporation to Outperform on Oct 12, 2026 with a price target of $112 (from $119). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- Leerink Partners — Outperform
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
Peers & ETF holders
CVS peers & ETF holders
Healthcare PlansMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| BlackRock, Inc. | ▼ Sell | 123,223,409 | 9.63% | $12.75B | 2026-08-07 |
| Vanguard Group Inc | ▲ Buy | 120,709,530 | 9.43% | $9.58B | 2026-01-29 |
| Capital World Investors | ▼ Sell | 74,951,955 | 5.86% | $7.75B | 2026-08-12 |
| Wellington Management Group LLP | ▲ Buy | 33,801,113 | 2.64% | $3.50B | 2026-08-14 |
| Geode Capital Management, LLC | ▲ Buy | 29,899,653 | 2.34% | $3.08B | 2026-08-12 |
| FMR LLC (Fidelity) | ▼ Sell | 28,920,617 | 2.26% | $2.99B | 2026-08-13 |
| Capital Research Global Investors | ▲ Buy | 24,329,151 | 1.90% | $2.52B | 2026-08-12 |
| Bank of America Corp | ▲ Buy | 23,188,670 | 1.81% | $2.40B | 2026-08-14 |
| JPMorgan Chase & Co | ▼ Sell | 22,112,970 | 1.73% | $2.29B | 2026-08-12 |
| Invesco Ltd. | ▼ Sell | 20,595,431 | 1.61% | $2.13B | 2026-08-14 |
| Morgan Stanley | ▲ Buy | 18,606,028 | 1.45% | $1.92B | 2026-08-13 |
| Norges Bank | ▼ Sell | 18,038,922 | 1.41% | $1.87B | 2026-08-12 |
| Goldman Sachs Group Inc | ▲ Buy | 13,411,807 | 1.05% | $1.39B | 2026-08-14 |
| Davis Selected Advisers | ▼ Sell | 11,865,916 | 0.93% | $1.23B | 2026-08-11 |
| Northern Trust Corp | ▼ Sell | 11,471,830 | 0.90% | $1.19B | 2026-08-13 |
| Glenview Capital Management, LLC | ▼ Sell | 4,824,799 | 0.38% | $499.13M | 2026-08-14 |
| Citadel Advisors LLC | ▼ Sell | 4,812,530 | 0.38% | $497.86M | 2026-09-02 |
| Wells Fargo & Company | ▼ Sell | 3,682,178 | 0.29% | $380.92M | 2026-08-14 |
| Viking Global Investors LP | ▲ New | 3,663,361 | 0.29% | $378.97M | 2026-08-14 |
| Janus Henderson Group plc | ▼ Sell | 3,536,861 | 0.28% | $254.02M | 2026-05-18 |
| AQR Capital Management LLC | ▲ Buy | 2,411,937 | 0.19% | $248.94M | 2026-08-14 |
| AllianceBernstein L.P. | ▲ Buy | 3,233,000 | 0.25% | $232.19M | 2026-08-14 |
| Millennium Management LLC | ▲ Buy | 2,164,833 | 0.17% | $223.95M | 2026-08-14 |
| Point72 Asset Management, L.P. | ▼ Sell | 1,961,032 | 0.15% | $202.87M | 2026-08-14 |
| Citigroup Inc | ▼ Sell | 1,811,857 | 0.14% | $187.44M | 2026-08-03 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Alan Armstrong | Senate | OK | ▲ Buy | $1K - $15K | 2026-03-27 | 2026-07-21 |
| John Boozman | Senate | AR | ▲ Buy | $1K - $15K | 2026-01-29 | 2026-02-15 |
| Dwight Evans | House | PA03 | ▼ Sell | $1K - $15K | 2025-11-21 | 2026-05-15 |
| Lisa McClain | House | MI09 | ▼ Sell | $1K - $15K | 2025-10-31 | 2025-11-21 |
| Lisa McClain | House | MI09 | ▼ Sell | $1K - $15K | 2025-10-30 | 2025-11-21 |
| Lisa McClain | House | MI09 | ▲ Buy | $1K - $15K | 2025-10-30 | 2025-11-21 |
| Adam Smith | House | WA09 | ▼ Sell | $1K - $15K | 2025-08-08 | 2025-08-08 |
| Rob Bresnahan | House | PA08 | ▼ Sell | $1K - $15K | 2025-05-15 | 2025-05-31 |
| Jefferson Shreve | House | IN06 | ▼ Sell | $15K - $50K | 2025-05-12 | 2025-06-22 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-04-01 | 2025-05-14 |
| Rob Bresnahan | House | PA08 | ▲ Buy | $1K - $15K | 2025-02-25 | 2025-03-27 |
| James French Hill | House | AR02 | ▼ Sell | $15K - $50K | 2025-01-31 | 2025-02-04 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2025-01-24 | 2025-02-11 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-01-15 | 2025-02-12 |
| Valerie Hoyle | House | OR04 | ▲ Buy | $1K - $15K | 2024-10-29 | 2025-09-12 |
| Tommy Tuberville | Senate | AL | ▼ Sell | $1K - $15K | 2024-08-26 | 2026-08-05 |
| Jerry Moran | Senate | - | ▼ Sell | $1K - $15K | 2023-12-14 | 2024-01-17 |
| Pete Ricketts | Senate | NE | ▼ Sell | $50K - $100K | 2023-09-21 | 2023-10-20 |
| Dan Sullivan | Senate | AK | ▼ Sell | $1K - $15K | 2023-08-22 | 2023-09-22 |
| Dan Sullivan | Senate | AK | ▼ Sell | $1K - $15K | 2023-01-10 | 2023-02-13 |
| Jerry Moran | Senate | - | ▼ Sell | $1K - $15K | 2021-12-21 | 2022-01-21 |
| Bill Cassidy | Senate | LA | ▼ Sell | $1K - $15K | 2020-11-05 | 2020-12-08 |
| Jerry Moran | Senate | - | ▲ Buy | $1K - $15K | 2020-08-21 | 2020-09-08 |
| Jerry Moran | Senate | - | ▼ Sell | $1K - $15K | 2019-09-25 | 2020-08-05 |
| Sheldon Whitehouse | Senate | RI | ▲ Buy | $1K - $15K | 2019-08-27 | 2019-10-08 |